Halozyme (NASDAQ: HALO) shareholder plans 150,000-share common stock sale

Rhea-AI Filing Summary

A shareholder of Halozyme Therapeutics, Inc. filed a Form 144 notice to sell 150,000 shares of common stock through J.P. Morgan Securities on the NASDAQ, with an approximate sale date of 02/03/2026. The filing lists an aggregate market value of $11,167,500 for these shares and notes that 117,597,000 shares of common stock were outstanding. The shares to be sold were acquired on 02/03/2026 via a stock option exercise paid in cash. The same shareholder previously sold multiple blocks of Halozyme common stock in November and December 2025, including 20,000-share sales on several November dates and 16,569 shares on 12/01/2025 with reported gross proceeds for each transaction.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 270 Park Avenue - 10th Floor New York NY 10017	150000	11167500	117597000	02/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/03/2026	Stock Option Exercise	Issuer			150000	02/03/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	11/10/2025	20000	1374342
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	11/11/2025	20000	1382599
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	11/12/2025	20000	1410990
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	12/01/2025	16569	1141923

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What stock sale does Halozyme (HALO) Form 144 disclose?

The Form 144 discloses a planned sale of 150,000 shares of Halozyme Therapeutics common stock. The shares are to be sold through J.P. Morgan Securities on the NASDAQ, with an approximate sale date of February 3, 2026 and an aggregate market value of $11,167,500.

How were the 150,000 Halozyme (HALO) shares being sold acquired?

The 150,000 Halozyme shares were acquired on February 3, 2026 through a stock option exercise from the issuer. The filing states that payment for these shares was made in cash on the same date, indicating a straightforward option exercise transaction immediately preceding the planned sale.

What is Halozyme’s share count context in this Form 144 filing?

The Form 144 states that 117,597,000 shares of Halozyme Therapeutics common stock were outstanding. This outstanding share figure provides baseline context for the 150,000-share proposed sale, helping investors gauge the relative size of the transaction against the company’s total common equity base.

Which broker and exchange are involved in the Halozyme (HALO) Form 144 sale?

The filing lists J.P. Morgan Securities LLC, located at 270 Park Avenue, New York, as the broker handling the transaction. The 150,000 Halozyme common shares are expected to be sold on the NASDAQ exchange, according to the securities information section of the notice.

What recent Halozyme (HALO) stock sales by the same shareholder are disclosed?

The Form 144 lists several prior sales by the same shareholder in the past three months. These include multiple 20,000-share common stock sales on November 10, 11 and 12, 2025, and a 16,569-share sale on December 1, 2025, each with separately reported gross proceeds amounts.

Who is the selling shareholder in the Halozyme (HALO) Form 144 filing?

The selling shareholder is identified as Helen Torley, care of Halozyme Therapeutics, Inc., at the company’s San Diego address. The form notes her as the person for whose account the securities are to be sold, consistent with Rule 144 disclosure requirements for control or restricted stock sales.